Evidence on Cardiovascular Risk of Calcium Supplementation in Post-Menopausal Women
The most authoritative evidence shows that calcium supplementation with or without vitamin D has no relationship—beneficial or harmful—with cardiovascular disease risk in generally healthy postmenopausal women, making option (c) the most accurate: calcium supplements may be associated with a small risk of CVD, but all the research is conflicting. 1
The Guideline Consensus
The 2016 joint guideline from the National Osteoporosis Foundation and American Society for Preventive Cardiology provides the highest-quality, most recent guidance on this issue. This guideline concludes with moderate-quality evidence (B level) that calcium intake from food or supplements—with or without vitamin D—shows no relationship to cardiovascular or cerebrovascular disease, mortality, or all-cause mortality in generally healthy adults. 1 Importantly, they specify that calcium intake not exceeding the tolerable upper limit (2000-2500 mg/day) should be considered safe from a cardiovascular standpoint.
Why the Evidence Appears Conflicting
The confusion stems from several meta-analyses that suggested increased cardiovascular risk, particularly:
A 2011 reanalysis of the Women's Health Initiative (WHI) found that in women not taking personal calcium supplements at baseline, calcium/vitamin D increased cardiovascular events (HR 1.13-1.22), but this effect disappeared in women already taking calcium supplements 2. This interaction was obscured in the original WHI analysis because 46% of participants were using personal calcium supplements.
Meta-analyses by Bolland and colleagues suggested a 24-31% increased risk of myocardial infarction with calcium supplements 2, 3
However, a more rigorous 2015 collaborative meta-analysis of 18 trials with 63,563 participants found no increased risk: the pooled relative risk for coronary heart disease was 1.02 (95% CI 0.96-1.09, p=0.51), and for all-cause mortality was 0.96 (95% CI 0.91-1.02, p=0.18) 4. This analysis used verified cardiovascular events from hospital records and death certificates, making it methodologically superior.
Key Distinctions in the Evidence
The original WHI study itself showed neutral cardiovascular effects (HR 1.04 for MI/CHD death, 95% CI 0.92-1.18; HR 0.95 for stroke, 95% CI 0.82-1.10) 5. The apparent increased risk only emerged in post-hoc subgroup analyses of women not taking personal supplements at baseline—a finding that raises concerns about data dredging.
Regarding option (d)—hormone replacement therapy: This is incorrect. The WHI calcium/vitamin D study was separate from the hormone therapy trials, and cardiovascular concerns in the reanalyses were attributed to calcium supplements themselves, not hormone therapy 2.
Regarding option (b)—dose relationship: There is no clear inverse relationship between calcium dose and cardiovascular risk. The evidence suggests either no relationship or possibly a threshold effect at very high doses.
Clinical Bottom Line
For your colleague, explain it this way:
The highest-quality 2016 guideline from NOF/ASPC states calcium supplements are cardiovascular-safe when not exceeding 2000-2500 mg/day total intake 1
Some older meta-analyses suggested small increased risks (10-30% relative risk increase), but these had methodological limitations including post-hoc subgroup analyses and self-reported outcomes
The most comprehensive meta-analysis with verified events found no cardiovascular signal 4
The practical recommendation: Prefer dietary calcium sources, but supplementation to correct dietary shortfalls is safe. Discontinuing supplements for cardiovascular concerns is unnecessary and may harm bone health when dietary intake is inadequate 1
Important Caveats
The evidence specifically applies to generally healthy postmenopausal women. Patients with renal impairment may have different risk profiles 3. The interaction between personal supplement use and trial supplementation in the WHI suggests that total calcium load matters more than supplement use per se—another reason to assess total dietary intake before prescribing supplements.
Note that the FDA drug labels provided 6 refer to atorvastatin calcium (a statin medication), not calcium supplements, and are not relevant to this question.